Trends in Cardiovascular Medicine
Volume 15, Issue 5 , Pages 163-169 , July 2005

Chemokines in Myocardial Ischemia

  • Nikolaos G. Frangogiannis

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Nikolaos Frangogiannis, MD, Section of Cardiovascular Sciences, One Baylor Plaza M/S F-602, Baylor College of Medicine, Houston, TX 77030, USA. Tel.: (+1) 713-798-4188; fax: (+1) 713-796-0015.
    • ,
  • Mark L. Entman

References 

  1. Abbott JD, Huang Y, Liu D, et al. Stromal cell-derived factor-1alpha plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation. 2004;110:3300–3305
  2. Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 1997;185:111–120
  3. Baggiolini M. Chemokines in pathology and medicine. J. Intern. Med. 2001;250:91–104
  4. Birdsall HH, Green DM, Trial J, et al. Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. Circulation. 1997;95:684–692
  5. Boyle EM, Kovacich JC, Hebert CA, et al. Inhibition of interleukin-8 blocks myocardial ischemia–reperfusion injury. J. Thorac. Cardiovasc. Surg. 1998;116:114–121
  6. Chandrasekar B, Smith JB, Freeman GL. Ischemia–reperfusion of rat myocardium activates nuclear factor-kB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation. 2001;103:2296–2302
  7. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ. Res. 2004;95:858–866
  8. Clark-Lewis I, Kim KS, Rajarathnam K, et al. Structure–activity relationships of chemokines. J. Leukoc. Biol. 1995;57:703–711
  9. Dewald O, Frangogiannis NG, Zoerlein M, et al. Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 2003;100:2700–2705
  10. Dewald O, Ren G, Duerr GD, et al. Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am. J. Pathol. 2004;164:665–677
  11. Dewald O, Ren G, Klemm C, et al. Development of murine fibrotic cardiomyopathy is dependent on monocyte chemoattractant protein 1. J. Am. Coll. Cardiol. 2004;43:230A
  12. Dewald O, Zymek P, Winkelmann K, et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ. Res. 2005;96:881–889
  13. Frangogiannis NG. Chemokines in the ischemic myocardium: from inflammation to fibrosis. Inflamm. Res. 2004;53:585–595
  14. Frangogiannis NG. The role of the chemokines in myocardial ischemia and reperfusion. Curr. Vasc. Pharmacol. 2004;2:163–174
  15. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98:699–710
  16. Frangogiannis NG, Mendoza LH, Lewallen M, et al. Induction and suppression of interferon-inducible protein 10 in reperfused myocardial infarcts may regulate angiogenesis. FASEB J. 2001;15:1428–1430
  17. Frangogiannis NG, Mendoza LH, Lindsey ML, et al. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. J. Immunol. 2000;165:2798–2808
  18. Frangogiannis NG, Mendoza LH, Smith CW, et al. Induction of the synthesis of the C-X-C chemokine interferon-gamma-inducible protein-10 in experimental canine endotoxemia. Cell Tissue Res. 2000;302:365–376
  19. Frangogiannis NG, Ren G, Dewald O, et al. The critical role of endogenous thrombospondin (TSP)-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005;111:2935–2942
  20. Frangogiannis NG, Shimoni S, Chang SM, et al. Active interstitial remodeling: an important process in the hibernating human myocardium. J. Am. Coll. Cardiol. 2002;39:1468–1474
  21. Frangogiannis NG, Shimoni S, Chang SM, et al. Evidence for an active inflammatory process in the hibernating human myocardium. Am. J. Pathol. 2002;160:1425–1433
  22. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc. Res. 2002;53:31–47
  23. Gerard C, Rollins BJ. Chemokines and disease. Nat. Immunol. 2001;2:108–115
  24. Gerszten RE, Garcia-Zepeda EA, Lim YC, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398:718–723
  25. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J. Biol. Chem. 1996;271:17779–17784
  26. Gu L, Tseng SC, Rollins BJ. Monocyte chemoattractant protein-1. Chem. Immunol. 1999;72:7–29
  27. Hayashidani S, Tsutsui H, Shiomi T, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2003;108:2134–2140
  28. Ivey CL, Williams FM, Collins PD, et al. Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit. Evidence for a role for C5a and interleukin-8. J. Clin. Invest. 1995;95:2720–2728
  29. Jo DY, Rafii S, Hamada T, Moore MA. Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. J. Clin. Invest. 2000;105:101–111
  30. Kaikita K, Hayasaki T, Okuma T, et al. Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am. J. Pathol. 2004;165:439–447
  31. Kakio T, Matsumori A, Ono K, et al. Roles and relationship of macrophages and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the ischemic and reperfused rat heart. Lab. Invest. 2000;80:1127–1136
  32. Kukielka GL, Smith CW, LaRosa GJ, et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J. Clin. Invest. 1995;95:89–103
  33. Kumar AG, Ballantyne CM, Michael LH, et al. Induction of monocyte chemoattractant protein-1 in the small veins of the ischemic and reperfused canine myocardium. Circulation. 1997;95:693–700
  34. Lakshminarayanan V, Lewallen M, Frangogiannis NG, et al. Reactive oxygen intermediates induce monocyte chemotactic protein-1 in vascular endothelium after brief ischemia. Am. J. Pathol. 2001;159:1301–1311
  35. Maekawa N, Wada H, Kanda T, et al. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J. Am. Coll. Cardiol. 2002;39:1229–1235
  36. Moser B, Loetscher P. Lymphocyte traffic control by chemokines. Nat. Immunol. 2001;2:123–128
  37. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996;382:635–638
  38. Nossuli TO, Frangogiannis NG, Knuefermann P, et al. Brief murine myocardial I/R induces chemokines in a TNF-α-independent manner: role of oxygen radicals. Am. J. Physiol. Heart Circ. Physiol. 2001;281:H2549–H2558
  39. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2002;283:R7–R28
  40. Ono K, Matsumori A, Furukawa Y, et al. Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab. Invest. 1999;79:195–203
  41. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701–705
  42. Peled A, Petit I, Kollet O, et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 1999;283:845–848
  43. Pillarisetti K, Gupta SK. Cloning and relative expression analysis of rat stromal cell derived factor-1 (SDF-1)1: SDF-1 alpha mRNA is selectively induced in rat model of myocardial infarction. Inflammation. 2001;25:293–300
  44. Rollins BJ. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol. Med. Today. 1996;2:198–204
  45. Rollins BJ. Chemokines. Blood. 1997;90:909–928
  46. Salcedo R, Ponce ML, Young HA, et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood. 2000;96:34–40
  47. Salvucci O, Yao L, Villalba S, et al. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood. 2002;99:2703–2711
  48. Shiraha H, Glading A, Gupta K, Wells A. IP-10 inhibits epidermal growth factor-induced motility by decreasing epidermal growth factor receptor-mediated calpain activity. J. Cell Biol. 1999;146:243–254
  49. Strieter RM, Polverini PJ, Arenberg DA, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J. Leukoc. Biol. 1995;57:752–762
  50. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 1995;270:27348–27357
  51. Tarzami ST, Cheng R, Miao W, et al. Chemokine expression in myocardial ischemia: MIP-2 dependent MCP-1 expression protects cardiomyocytes from cell death. J. Mol. Cell. Cardiol. 2002;34:209–221
  52. Tarzami ST, Miao W, Mani K, et al. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia–reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation. 2003;108:2387–2392
  53. Uguccioni M, D'Apuzzo M, Loetscher M, et al. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1a and MIP-1b on human monocytes. Eur. J. Immunol. 1995;25:64–68

PII: S1050-1738(05)00086-1

doi: 10.1016/j.tcm.2005.06.005

Trends in Cardiovascular Medicine
Volume 15, Issue 5 , Pages 163-169 , July 2005

Article Tools

* Image Usage & Resolution